Helsinki-based Surgify Medical secured $7.8 million (€7 million) in a Series A round led by Zeiss Ventures, with participation from the European Innovation Council Fund and existing investors. Surgify designs the Halo device, a bone-cutting tool offering precision and unique protection against injury to soft tissues such as nerves and blood vessels during surgery.
Halo, already approved in Europe and the U.S., combines effective bone resection with soft tissue safety features, reducing risks associated with conventional surgical drills. Surgify aims to expand beyond the Nordic market into broader European and U.S. territories with this new funding.
Visa Sippola, co-founder and CEO, emphasized the backing of global surgical technology expertise and European innovation support as key factors for Surgify’s growth and international reach.
Follow MEDWIRE.AI for the latest in surgical innovation.
